Muriel Debois

3.1k total citations
39 papers, 1.6k citations indexed

About

Muriel Debois is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Muriel Debois has authored 39 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 20 papers in Pulmonary and Respiratory Medicine and 9 papers in Immunology. Recurrent topics in Muriel Debois's work include Prostate Cancer Treatment and Research (14 papers), Cancer Immunotherapy and Biomarkers (9 papers) and Prostate Cancer Diagnosis and Treatment (9 papers). Muriel Debois is often cited by papers focused on Prostate Cancer Treatment and Research (14 papers), Cancer Immunotherapy and Biomarkers (9 papers) and Prostate Cancer Diagnosis and Treatment (9 papers). Muriel Debois collaborates with scholars based in Belgium, Netherlands and United Kingdom. Muriel Debois's co-authors include Laurence Collette, Peter Whelan, Eric Van Cutsem, S.K. Sundaram, Bart Spiessens, Wolfgang Loidl, Santiago Isorna, J Casselman, Urs E. Studer and Theo de Reijke and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Surgery and The Lancet Oncology.

In The Last Decade

Muriel Debois

39 papers receiving 1.6k citations

Peers

Countries citing papers authored by Muriel Debois

Since Specialization

Citations

This map shows the geographic impact of Muriel Debois's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Muriel Debois with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Muriel Debois more than expected).

Fields of papers citing papers by Muriel Debois

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Muriel Debois. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Muriel Debois. The network helps show where Muriel Debois may publish in the future.

Co-authorship network of co-authors of Muriel Debois

This figure shows the co-authorship network connecting the top 25 collaborators of Muriel Debois. A scholar is included among the top collaborators of Muriel Debois based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Muriel Debois. Muriel Debois is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A phase IIA extension study evaluating the effect of booster vaccination with a fractional dose of RTS,S/AS01E in a controlled human malaria infection challenge 2021 ·Vaccine ·James E. Moon, (unknown), Jason A. Regules, Muriel Debois, Elizabeth H. Duncan, Martha Sedegah, Ilin Chuang, Cynthia Lee, (unknown), Lindsey S. Garver, Karen Ivinson, Evelina Angov, Danielle Morelle, Marc Lievens, Christian F. Ockenhouse, Viseth Ngauy, Opokua Ofori‐Anyinam	7
2	Persistence of vaccine-elicited immune response up to 14 years post-HIV gp120-NefTat/AS01B vaccination 2020 ·Vaccine ·Olivier Van Der Meeren, Erik Jongert, Kelly E. Seaton, Marguerite Koutsoukos, Annelies Aerssens, (unknown), Muriel Debois, Michel Janssens, Geert Leroux‐Roels, (unknown), Sheetal Sawant, Nicole L. Yates, Georgia D. Tomaras, Isabel Leroux‐Roels, François Roman	3
3	A Th1/IFNγ Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non–Small Cell Lung Cancer 2019 ·Clinical Cancer Research ·Benjamin Dizier, Andrea Callegaro, Muriel Debois, Brigitte Dréno, Peter Hersey, Helen Gogas, John M. Kirkwood, Johan Vansteenkiste, Lecia V. Sequist, Djordje Atanackovic, Jelle J. Goeman, Hans C. van Houwelingen, Susana Alicia Salceda, (unknown), Patrick Therasse, C. Debruyne, Bart Spiessens, Vincent Brichard, Jamila Louahed, Fernando Ulloa‐Montoya	13
4	Pandemic influenza virus vaccines boost hemagglutinin stalk-specific antibody responses in primed adult and pediatric cohorts 2019 ·npj Vaccines ·Raffael Nachbagauer, Bruno Salaun, Daniel Stadlbauer, Mohammad Amin Behzadi, Damien Friel, Arvind Rajabhathor, Angela Choi, Randy A. Albrecht, Muriel Debois, Adolfo Garcı́a-Sastre, (unknown), Weina Sun, Peter Palese, Corey P. Mallett, Bruce L. Innis, Florian Krammer, Carine Claeys	18
5	Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non–Small Cell Lung Cancer: A Phase I Dose Escalation Study 2016 ·Journal of Thoracic Oncology ·Jean-Louis Pujol, Tommaso De Pas, Achim Rittmeyer, Eric Vallières, Bartosz Kubisa, E. Levchenko, Sebastian Wiesemann, Gregory A. Masters, Robert Shen, Sergei Tjulandin, Hans‐Stefan Hofmann, Nicolas Vanhoutte, Bruno Salaun, Muriel Debois, (unknown), (unknown), Jamila Louahed, Vincent Brichard, Frédéric Lehmann	71
6	Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non-Small-Cell Lung Cancer 2015 ·Journal of Thoracic Oncology ·Jean-Louis Pujol, Johan Vansteenkiste, Tommaso Martino De Pas, Djordje Atanackovic, Martin Reck, Michiel Thomeer, Jean-Yves Douillard, Gianpiero Fasola, Vanessa Potter, Paul Taylor, Lionel Bosquée, Robert Scheubel, (unknown), Muriel Debois, (unknown), Jamila Louahed, Vincent Brichard, Frédéric Lehmann	51
7	MAGE-A3 GENE EXPRESSION FREQUENCY AND DEMOGRAPHY DATA OF STAGE IB-IIIA NSCLC PATIENTS FROM ONGOING MAGRIT PHASE III TRIAL EVALUATING MAGE-A3 ANTIGEN SPECIFIC CANCER IMMUNOTHERAPEUTIC (ASCI) AS ADJUVANT TREATMENT 2010 ·Annals of Oncology ·(unknown), Jacek Jassem, (unknown), M Yoshimura, Francovito Piantedosi, Petr Zatloukal, (unknown), Muriel Debois, C. Debruyne, Johan Vansteenkiste	6
8	Adjusted significance levels for subgroup analyses in clinical trials 2010 ·Contemporary Clinical Trials ·Bart Spiessens, Muriel Debois	58
9	MAGRIT phase III trial in adjuvant NSCLC: MAGE-A3 gene expression frequency on the first 2150 patients screened and demographics of first patients randomized 2009 ·Journal of Thoracic Oncology ·Tommaso De Pas, Joo-Hang Kim, Paul Zarogoulidis, M. Zieliński, Jubrail Dahabreh, Tõnu Vanakesa, (unknown), Emilio Esteban, Hans Hoffman, Sumitra Thongprasert, Muriel Debois, Jean-Yves Douillard, Nasser K. Altorki, C. Debruyne, Johan Vansteenkiste	2
10	9021 Preliminary results of MAGE-A3 expression and baseline demographic data from MAGRIT, a large phase III trial of MAGE-A3 ASCI (Antigen-Specific Cancer Immunotherapeutic) in adjuvant NSCLC 2009 ·European Journal of Cancer Supplements ·M. Zieliński, (unknown), (unknown), M. Reck, János Strausz, (unknown), (unknown), (unknown), Muriel Debois, C. Debruyne	3
11	Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015 2007 ·Annals of Oncology ·C.-H. Köhne, Jacques De Grève, J. T. Hartmann, István Láng, Philippe Vergauwe, Karl‐Friedrich Becker, D. Braumann, E. Joosens, Lothar Müller, Jos Janssens, Carsten Bokemeyer, Peter Reimer, Hartmut Link, E. Späth‐Schwalbe, H. Wilke, Harry Bleiberg, Jan Van den Brande, Muriel Debois, Ullrich Bethe, Eric Van Cutsem	127
12	Using PSA to Guide Timing of Androgen Deprivation in Patients with T0–4 N0–2 M0 Prostate Cancer not Suitable for Local Curative Treatment (EORTC 30891) 2007 ·European Urology ·Urs E. Studer, Laurence Collette, Peter Whelan, Walter Albrecht, J Casselman, Theo de Reijke, H Knönagel, Wolfgang Loidl, Santiago Isorna, S.K. Sundaram, Muriel Debois	79
13	A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer 2007 ·Cancer Chemotherapy and Pharmacology ·Andrew R. Clamp, Patrick Schöffski, Juan W. Valle, R. H. Wilson, Sandrine Marréaud, (unknown), Muriel Debois, Denis Lacombe, Chris Twelves, (unknown), Gordon C. Jayson, (unknown)	16
14	Immediate or Deferred Androgen Deprivation for Patients With Prostate Cancer Not Suitable for Local Treatment With Curative Intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891 2006 ·Journal of Clinical Oncology ·Urs E. Studer, Peter Whelan, Walter Albrecht, J Casselman, Theo de Reijke, D. Hauri, Wolfgang Loidl, Santiago Isorna, S.K. Sundaram, Muriel Debois, Laurence Collette	225
15	Capecitabine plus irinotecan versus 5-FU/FA/irinotecan ± celecoxib in first line treatment of metastatic colorectal cancer (CRC). Long-term results of the prospective multicenter EORTC phase III study 40015 2006 ·Journal of Clinical Oncology ·Jacques De Grève, (unknown), Julia Hartmann, (unknown), Philippe Vergauwe, Karl‐Friedrich Becker, D. Braumann, Muriel Debois, Ullrich Bethe, Eric Van Cutsem	25
16	IS THE DEGREE OF PSA DECLINE AFTER IMMEDIATE ANDROGEN DEPRIVATION A PROGNOSTIC FACTOR FOR OUTCOME IN PATIENTS WITH T0-4 N0 M0 PROSTATE CANCER NOT SUITABLE FOR LOCAL TREATMENT WITH CURATIVE INTENT? (RESULTS FROM THE EORTC 30891 TRIAL) 2006 ·European Urology Supplements ·Laurence Collette, Urs E. Studer, Peter Whelan, W. Albrecht, J Casselman, T.M. De Reijke, D. Hauri, Wolfgang Loidl, Santiago Isorna, S.K. Sundaram, Muriel Debois	5
17	Phase III Trial of Satraplatin, an Oral Platinum plus Prednisone vs. Prednisone alone in Patients with Hormone-Refractory Prostate Cancer 2005 ·Oncology ·Cora N. Sternberg, Peter Whelan, John Hetherington, (unknown), P. H. Th. J. Slee, K. Vekemans, P. Van Erps, Christine Théodore, (unknown), R.T.D. Oliver, David Lebwohl, Muriel Debois, Alfredo Zurlo, Laurence Collette	167
18	Adjuvant regional chemotherapy and systemic chemotherapy versus systemic chemotherapy alone in patients with stage II–III colorectal cancer: a multicentre randomised controlled phase III trial 2005 ·The Lancet Oncology ·Bernard Nordlinger, Philippe Rougier, Jean‐Pierre Arnaud, Muriel Debois, (unknown), Jean-Claude Ollier, (unknown), P Lasser, (unknown), (unknown), Jean‐François Seitz, (unknown), Harry Bleiberg, (unknown), Thierry Conroy, Olivier Bouché, Thierry Morin, Liliana Baila, Eric Van Cutsem, Laurent Bedenne	39
19	EARLY VERSUS DELAYED ENDOCRINE TREATMENT OF pN1-3 M0 PROSTATE CANCER WITHOUT LOCAL TREATMENT OF THE PRIMARY TUMOR: RESULTS OF EUROPEAN ORGANISATION FOR THE RESEARCH AND TREATMENT OF CANCER 30846—A PHASE III STUDY 2004 ·The Journal of Urology ·Fritz H. Schröder, Karl H. Kurth, Sophie D. Fosså, (unknown), (unknown), Muriel Debois, Laurence Collette	80
20	Metastatic Prostate Cancer Treated by Flutamide versus Cyproterone Acetate 2003 ·European Urology ·Fritz H. Schröder, Peter Whelan, Theo M. de Reijke, Karl H. Kurth, M. Pavone‐Macaluso, J Mattelaer, Roland F. van Velthoven, Muriel Debois, Laurence Collette	41

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact